CL2013000962A1 - Metodo para porducir un copolimero de carboximetilcelulosa sodica con un grado de sustitucion de 0,35 a 0,80 y gosipol; composicion farmaceutica; combinacion que lo comprende junto a uno o mas medicamentos neurolepticos, antidepresivos o anticonvulsivos; metodo de tratamiento; y uso en trastornos autistas y alteraciones cognitivas. - Google Patents

Metodo para porducir un copolimero de carboximetilcelulosa sodica con un grado de sustitucion de 0,35 a 0,80 y gosipol; composicion farmaceutica; combinacion que lo comprende junto a uno o mas medicamentos neurolepticos, antidepresivos o anticonvulsivos; metodo de tratamiento; y uso en trastornos autistas y alteraciones cognitivas.

Info

Publication number: CL2013000962A1
Authority: CL; Chile
Prior art keywords: disorders; gosipol; neuroleptic; antidepressant; producing
Prior art date: 2010-10-11

Application number

CL2013000962A

Other languages

English (en)

Inventor

Feliz Ivanovich Ershov

Vladimir Georgievich Nesterenko

Abdushukur Abdukhalilovich Sarymsakov

Natalya Uryevna Alekseeva

Original Assignee

Ltd Liability Company Nearmedic Plus

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-10-11

Filing date

2013-04-10

Publication date

2013-12-06

2013-04-10 Application filed by Ltd Liability Company Nearmedic Plus filed Critical Ltd Liability Company Nearmedic Plus

2013-12-06 Publication of CL2013000962A1 publication Critical patent/CL2013000962A1/es

Links

208000020706 Autistic disease Diseases 0.000 title 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 title 1
230000001773 anti-convulsant effect Effects 0.000 title 1
230000001430 anti-depressive effect Effects 0.000 title 1
239000001961 anticonvulsive agent Substances 0.000 title 1
239000000935 antidepressant agent Substances 0.000 title 1
229940005513 antidepressants Drugs 0.000 title 1
229960003965 antiepileptics Drugs 0.000 title 1
239000001768 carboxy methyl cellulose Substances 0.000 title 1
208000010877 cognitive disease Diseases 0.000 title 1
229940079593 drug Drugs 0.000 title 1
239000003814 drug Substances 0.000 title 1
QBKSWRVVCFFDOT-UHFFFAOYSA-N gossypol Chemical compound CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 QBKSWRVVCFFDOT-UHFFFAOYSA-N 0.000 title 1
229950005277 gossypol Drugs 0.000 title 1
238000004519 manufacturing process Methods 0.000 title 1
238000002483 medication Methods 0.000 title 1
238000000034 method Methods 0.000 title 1
239000003176 neuroleptic agent Substances 0.000 title 1
230000000701 neuroleptic effect Effects 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 title 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 title 1
238000006467 substitution reaction Methods 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/717—Celluloses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B11/00—Preparation of cellulose ethers
- C08B11/02—Alkyl or cycloalkyl ethers
- C08B11/04—Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals
- C08B11/10—Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals substituted with acid radicals
- C08B11/12—Alkyl or cycloalkyl ethers with substituted hydrocarbon radicals substituted with acid radicals substituted with carboxylic radicals, e.g. carboxymethylcellulose [CMC]
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B15/00—Preparation of other cellulose derivatives or modified cellulose, e.g. complexes
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B15/00—Preparation of other cellulose derivatives or modified cellulose, e.g. complexes
- C08B15/02—Oxycellulose; Hydrocellulose; Cellulosehydrate, e.g. microcrystalline cellulose

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Materials Engineering (AREA)
Polymers & Plastics (AREA)
Biochemistry (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Psychiatry (AREA)
Molecular Biology (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Polysaccharides And Polysaccharide Derivatives (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

CL2013000962A 2010-10-11 2013-04-10 Metodo para porducir un copolimero de carboximetilcelulosa sodica con un grado de sustitucion de 0,35 a 0,80 y gosipol; composicion farmaceutica; combinacion que lo comprende junto a uno o mas medicamentos neurolepticos, antidepresivos o anticonvulsivos; metodo de tratamiento; y uso en trastornos autistas y alteraciones cognitivas. CL2013000962A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
RU2010141697/05A RU2453559C1 (ru)	2010-10-11	2010-10-11	Способ получения сополимера натрийкарбоксиметилцеллюлозы и госсипола и его применение в комплексной терапии пациентов с аутистическими расстройствами и когнитивными нарушениями

Publications (1)

Publication Number	Publication Date
CL2013000962A1 true CL2013000962A1 (es)	2013-12-06

Family

ID=45938511

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CL2013000962A CL2013000962A1 (es)	2010-10-11	2013-04-10	Metodo para porducir un copolimero de carboximetilcelulosa sodica con un grado de sustitucion de 0,35 a 0,80 y gosipol; composicion farmaceutica; combinacion que lo comprende junto a uno o mas medicamentos neurolepticos, antidepresivos o anticonvulsivos; metodo de tratamiento; y uso en trastornos autistas y alteraciones cognitivas.
CL2015001180A CL2015001180A1 (es)	2010-10-11	2015-05-05	Combinacion farmaceutica que comprende un copolimero de carboximetilcelulosa sodica con un grado de sustitucion de 0,35 a 0,80 y gosipol o un medicamento para el tratamiento de trastornos cognitivos seleccionado de neurolepticos, antidepresivos, anticonvulsivos o una combinacion de los mismos.

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
CL2015001180A CL2015001180A1 (es)	2010-10-11	2015-05-05	Combinacion farmaceutica que comprende un copolimero de carboximetilcelulosa sodica con un grado de sustitucion de 0,35 a 0,80 y gosipol o un medicamento para el tratamiento de trastornos cognitivos seleccionado de neurolepticos, antidepresivos, anticonvulsivos o una combinacion de los mismos.

Country Status (27)

Country	Link
US (1)	US9078916B2 (es)
EP (1)	EP2628754B8 (es)
JP (1)	JP5690944B2 (es)
CN (1)	CN103189393B (es)
AU (1)	AU2011314406B2 (es)
BR (1)	BR112013008888B1 (es)
CA (2)	CA2811583C (es)
CL (2)	CL2013000962A1 (es)
CO (1)	CO6731081A2 (es)
CY (1)	CY1119413T1 (es)
DK (1)	DK2628754T3 (es)
EA (2)	EA024810B1 (es)
EC (1)	ECSP13012613A (es)
ES (1)	ES2643167T3 (es)
GE (1)	GEP201706607B (es)
HR (1)	HRP20171330T1 (es)
HU (1)	HUE034920T2 (es)
LT (1)	LT2628754T (es)
PE (1)	PE20140200A1 (es)
PL (1)	PL2628754T3 (es)
PT (1)	PT2628754T (es)
RS (1)	RS56257B1 (es)
RU (1)	RU2453559C1 (es)
SI (1)	SI2628754T1 (es)
SM (1)	SMT201700497T1 (es)
UA (2)	UA108126C2 (es)
WO (1)	WO2012050483A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2499002C1 (ru) *	2012-06-14	2013-11-20	Общество С Ограниченной Ответственностью "Ниармедик Плюс"	Конъюгаты госсипола и натрийкарбоксиметилцеллюлозы, способы их получения и противовирусные средства на их основе
RU2577539C2 (ru) *	2014-06-17	2016-03-20	Общество С Ограниченной Ответственностью "Ниармедик Плюс"	Полимерные производные госсипола, способ их получения и фармацевтическая композиция на их основе
RU2754067C2 (ru) *	2018-05-18	2021-08-25	Общество с ограниченной ответственностью "НИАРМЕДИК ФАРМА"	Противомикробная композиция на основе полифенолов и полисахаридов, способ ее получения и применение
RU2746504C1 (ru) *	2020-02-27	2021-04-14	Ниармедик Интернэшнл Лимитед	Противомикробные средства на основе бета-глюканов, способы их получения и применения
CN114622407B (zh) *	2022-04-01	2023-09-19	浙江隆腾医用新材料有限公司	一种羧甲基纤维素钠纤维的洗脱方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2002755C1 (ru) *	1991-02-04	1993-11-15	Научно-исследовательский институт эпидемиологии и микробиологии им.Н.Ф.Гамалеи РАМН	Производное целлюлозы и госсипола, обладающее интерферониндуцирующим и противовирусным действием
RU2222548C2 (ru) *	2000-07-21	2004-01-27	Зао "Ниармедик Плюс"	Применение производного целлюлозы и госсипола в качестве радиопротекторного, противоинфекционного и потенциирующего средства, усовершенствованный способ его получения и фармацевтическая композиция на его основе
AU2003247515A1 (en) *	2002-06-10	2003-12-22	Wyeth	Novel formate salt of o-desmethyl-venlafaxine
DE10226494A1 (de) *	2002-06-14	2004-01-08	Lts Lohmann Therapie-Systeme Ag	Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen
RU2238122C1 (ru) *	2003-01-20	2004-10-20	Ооо "Ниармедик Плюс"	Противоинфекционный фармацевтический препарат
RU2270708C1 (ru) *	2004-05-26	2006-02-27	Ооо "Ниармедик Плюс"	Натриевая соль сополимера карбоксиметилцеллюлозы и госсипола, фармацевтическая композиция и способ профилактики или лечения вирусных заболеваний
US20060144723A1 (en) *	2004-11-02	2006-07-06	Mary Fuller	Device for securing valuables
AU2006261893A1 (en) *	2005-06-23	2007-01-04	Combinatorx, Incorporated	Improved dosage forms for movement disorder treatment
US20090285865A1 (en) *	2008-05-14	2009-11-19	Shalaby Shalaby W	Palatable, solid oral formulations for male chemical sterilization

2010
- 2010-10-11 RU RU2010141697/05A patent/RU2453559C1/ru active
2011
- 2011-06-10 UA UAA201305876A patent/UA108126C2/ru unknown
- 2011-10-06 SM SM20170497T patent/SMT201700497T1/it unknown
- 2011-10-06 RS RS20170877A patent/RS56257B1/sr unknown
- 2011-10-06 EA EA201390530A patent/EA024810B1/ru active IP Right Revival
- 2011-10-06 HU HUE11832823A patent/HUE034920T2/en unknown
- 2011-10-06 UA UAA201411350A patent/UA108975C2/ru unknown
- 2011-10-06 JP JP2013533814A patent/JP5690944B2/ja not_active Expired - Fee Related
- 2011-10-06 PT PT118328236T patent/PT2628754T/pt unknown
- 2011-10-06 PL PL11832823T patent/PL2628754T3/pl unknown
- 2011-10-06 SI SI201131286T patent/SI2628754T1/en unknown
- 2011-10-06 EA EA201690544A patent/EA031316B1/ru active IP Right Revival
- 2011-10-06 AU AU2011314406A patent/AU2011314406B2/en not_active Ceased
- 2011-10-06 CA CA2811583A patent/CA2811583C/en not_active Expired - Fee Related
- 2011-10-06 WO PCT/RU2011/000785 patent/WO2012050483A1/ru not_active Ceased
- 2011-10-06 CN CN201180048898.4A patent/CN103189393B/zh not_active Expired - Fee Related
- 2011-10-06 BR BR112013008888-5A patent/BR112013008888B1/pt not_active IP Right Cessation
- 2011-10-06 GE GEAP201113083A patent/GEP201706607B/en unknown
- 2011-10-06 CA CA2896450A patent/CA2896450A1/en not_active Abandoned
- 2011-10-06 DK DK11832823.6T patent/DK2628754T3/da active
- 2011-10-06 PE PE2013000829A patent/PE20140200A1/es active IP Right Grant
- 2011-10-06 ES ES11832823.6T patent/ES2643167T3/es active Active
- 2011-10-06 EP EP11832823.6A patent/EP2628754B8/en active Active
- 2011-10-06 HR HRP20171330TT patent/HRP20171330T1/hr unknown
- 2011-10-06 LT LTEP11832823.6T patent/LT2628754T/lt unknown
- 2011-10-06 US US13/877,416 patent/US9078916B2/en not_active Expired - Fee Related
2013
- 2013-04-10 CL CL2013000962A patent/CL2013000962A1/es unknown
- 2013-05-09 EC ECSP13012613 patent/ECSP13012613A/es unknown
- 2013-05-10 CO CO13117014A patent/CO6731081A2/es unknown
2015
- 2015-05-05 CL CL2015001180A patent/CL2015001180A1/es unknown
2017
- 2017-09-14 CY CY20171100974T patent/CY1119413T1/el unknown

Also Published As

Publication number	Publication date
CA2811583A1 (en)	2012-04-19
CY1119413T1 (el)	2018-03-07
RU2010141697A (ru)	2012-04-20
ES2643167T3 (es)	2017-11-21
PL2628754T3 (pl)	2017-12-29
SI2628754T1 (en)	2017-11-30
EA201690544A1 (ru)	2016-07-29
BR112013008888A2 (pt)	2016-06-28
EP2628754B8 (en)	2017-10-25
JP2013540866A (ja)	2013-11-07
PT2628754T (pt)	2017-10-19
CO6731081A2 (es)	2013-08-15
CN103189393B (zh)	2015-09-30
AU2011314406B2 (en)	2016-08-11
CA2811583C (en)	2016-03-22
AU2011314406A1 (en)	2013-05-23
EA031316B1 (ru)	2018-12-28
BR112013008888B1 (pt)	2021-01-05
WO2012050483A1 (ru)	2012-04-19
EP2628754A1 (en)	2013-08-21
CL2015001180A1 (es)	2015-08-28
UA108126C2 (uk)	2015-03-25
HUE034920T2 (en)	2018-03-28
RU2453559C1 (ru)	2012-06-20
US9078916B2 (en)	2015-07-14
EP2628754B1 (en)	2017-07-12
US20130266534A1 (en)	2013-10-10
JP5690944B2 (ja)	2015-03-25
HRP20171330T1 (hr)	2017-10-20
SMT201700497T1 (it)	2017-11-15
RS56257B1 (sr)	2017-11-30
EA201390530A1 (ru)	2013-07-30
PE20140200A1 (es)	2014-02-21
EP2628754A4 (en)	2014-03-26
GEP201706607B (en)	2017-01-25
DK2628754T3 (da)	2017-11-20
LT2628754T (lt)	2017-11-10
CN103189393A (zh)	2013-07-03
ECSP13012613A (es)	2013-10-31
EA024810B1 (ru)	2016-10-31
UA108975C2 (uk)	2015-06-25
CA2896450A1 (en)	2012-04-19

Publication	Publication Date	Title
HUE043175T2 (hu)	2019-08-28	Szintetikus triterpenoidok és alkalmazásuk betegség kezelésében
BRPI1009481A2 (pt)	2016-03-01	compostos de 2-acetamido-5-aril-1,2,4-triazolonas substituídas, seu processo de preparação, seu uso e medicamento compreendendo os mesmos
CL2008000531A1 (es)	2008-09-22	Compuestos derivados de heterociclos, inhibidores de la aspartilproteasa; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de enfermedades cardiovasculares, cognitivas y neurodegenerativas tales como la enfermeda
IL211400A0 (en)	2011-05-31	Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof
CL2007003061A1 (es)	2008-08-01	Compuestos derivados de 3,5-dioxi-benzamida; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad mediada a traves de glk, tal como la diabetes tipo 2.
BR112012002331A2 (pt)	2019-09-24	composição antiviral, composição farmacêutica e uso de quantidade efetiva de composição farmacêutica
CL2012000620A1 (es)	2013-09-06	Formulaciones farmaceuticas de un anticuerpo anti cd-20; uso de la formulacion para tratar enfermedad o trastorno que pueda corregirse mediante tratamiento con anticuerpo anti-cd20.
CL2016002132A1 (es)	2017-06-09	Uso de una cantidad de laquinimod, que sirve para preparar un medicamento para tratar un paciente humano afectado con esclerosis múltiple o que presenta un síndrome clínicamente aislado; un paquete, una cantidad de laquinimod y una composición farmacéutica del mismo.
BRPI0912717A2 (pt)	2014-12-23	Composição farmacêutica, e, uso de 5-azacitidina
BRPI0820997A2 (pt)	2014-12-23	Comprimidos de desintegração oral compreendendo difenidramina.
EA201491009A1 (ru)	2015-10-30	Гель лизата тромбоцитов
BR112012004335A2 (pt)	2015-09-08	composto, composição farmacêutica, e, uso do composto.
CL2007003640A1 (es)	2008-07-11	Compuestos derivados de benzamida; composicion farmaceutica que comprende dichos compuestos; y su uso para el tratamiento en que la afeccion es dolor, tales como dolor lumbar y cervical, migrana, dismenorrea, dolor de muelas, entre otros.
BRPI1006040A2 (pt)	2016-05-10	uso de composições farmacêuticas, tipo de curativo médico, e, tipo de caixa de medicamento
BR112013016212A2 (pt)	2018-05-15	composição aquosa de cuidado oral compreendendo goma xantana, goma de celulose e carbômero.
EP2474522A4 (en)	2013-03-20	AGOME ELITE AND PHARMACEUTICAL COMPOSITIONS THEREOF
ES2446643R1 (es)	2015-03-06	Composiciones farmacéuticas combinadas y su uso para preparar un medicamento destinado al tratamiento del vértigo, la cinetosis y la distonía vegetativa-vascular
EA201200484A1 (ru)	2012-12-28	Фармацевтическая композиция с действующими веществами - метформином и ситаглиптином или вилдаглиптином
CL2008002486A1 (es)	2008-12-26	Comprimido divisible de liberacion modificada que comprende glicazida, un derivado de celulosa elegido entre: hmc, hec, hpc y/o hpmc y un aglutinante elegido entre: maltodextrina, polividona o hpmc; uso para tratar diabetes.
CL2013001411A1 (es)	2014-03-28	Peptido que posee actividad antiapoptotica; conjugado que lo comprende; composicion farmaceutica que lo comprende; y su uso para tratar una enfermedad o condicion asociada con apoptosis en un sujeto.
BR112013014189A2 (pt)	2017-08-01	composição farmacêutica que compreende transcinamaldeíco e o uso da mesma no tratamento de infecções
BRPI1006953A2 (pt)	2016-04-26	composição farmacêutica, e, uso de uma composição
CL2012003322A1 (es)	2014-03-28	Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer.
CL2014000671A1 (es)	2014-10-03	Composicion farmaceutica que comprende rifabutina, claritromicina y clofazimina; y su uso para tratar una enfermedad autoinmune tal como esclerosis multiple y sus sintomas asociados, tiroiditis de hashimoto y sindrome de melkersson o sarcoidosis.
CL2014003525A1 (es)	2015-04-10	Composicion farmaceutica que comprende fimasartan, hidroclorotiazida y un aglutinante; procedimiento de preparacion; su uso en el tratamiento de hipertension.